On March 26, 2026 VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, reported the presentation of an abstract at the European Lung Cancer Conference (ELCC) in Copenhagen, Denmark this week. The poster highlighted the use of its Nu.Q Cancer assays in the management of lung cancer patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster 244P : Preoperative Nucleosome Liquid Biopsy for Prognostic Stratification in Lung Cancer With Treatment Correlation1

Joint lead author Dr. Pei-Hsing Chen, Assistant Professor, Surgical Department, National Taiwan University Hospital, Taipei City, Taiwan, said:

"A key finding from this study was that measuring preoperative H3K27Me3-nucleosomes using Volition’s simple blood test allows us to identify which Non Small Cell Lung Cancer patients are most likely to benefit from closer follow-ups or secondary cancer treatment.

"While high H3K27Me3-nucleosome levels predicted poorer recurrence-free and overall survival outcomes, low H3K27me3 levels indicated significantly better outcomes.

"Volition’s Nu.Q H3K27Me3-nucleosome levels may also help identify micro-metastatic disease and support systemic treatment decision-making in high-risk patients.

"The Nu.Q Cancer technology supports a practical approach to empower clinicians to make more informed treatment decisions and provides valuable new monitoring capabilities throughout the patient journey."

Dr Andrew Retter, Medical Consultant, Volition, said:

"Nu.Q Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring.

"Research conducted by our long-term collaborators in Taiwan and Lyon1-4 consistently demonstrates that our Nu.Q Cancer technology empowers clinicians to make more informed treatment decisions and provides valuable new monitoring capabilities throughout the patient journey.

"By enriching clinical prognostication, Nu.Q Cancer helps identify the most appropriate treatment pathway for an individual patient, supporting efforts to improve overall survival and deliver patient-centred care.

"We are now on the path to the first use of Nu.Q in clinical practice, an exciting prospect which is core to Volition’s mission, using our tests to help save lives"

Pei-Hsing Chen et al "Nucleosome Liquid Biopsy for Prognostic Stratification in Lung Cancer With Treatment Correlation" Poster 244P ELCC 2026
Grolleau E, et al. Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling. Biomolecules. 2023;13(8):1255. View Source
Couraud S, et al Baseline values of circulating nucleosomes in Lung Cancer: NUCLEO-LUNG study. ELCC 2024 Poster
Marie Piecyk et al, "H3K27Me3-nucleosome is a strong prognostic biomarker in Non-Small Cell Lung Cancer: interim results from the analysis of up to 832 patients at baseline" Poster 395 ELCC 2025

(Press release, VolitionRX, MAR 26, 2026, View Source [SID1234663958])